Healthcare · Biotechnology
Price
$16.00
Market Cap
$92.8M
Employees
15
Beta
-0.88
Avg Volume
251,903
CEO
Stephen Uden
Business Description
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-10.06
Stock Price: $16.00
EPS (Diluted): -1.59
EPS (Diluted): -1.59
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.53
Stock Price: $16.00
Total Equity: $57.96M
Shares: 5,629,370
Total Equity: $57.96M
Shares: 5,629,370
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.01
Market Cap: $92.80M
Total Debt: $0.00
Cash: $31.37M
EBITDA: -$27.97M
Total Debt: $0.00
Cash: $31.37M
EBITDA: -$27.97M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$-292,759
Market Cap: $92.80M
Total Debt: $0.00
Cash: $31.37M
Total Debt: $0.00
Cash: $31.37M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
36.02
Stock Price: $16.00
Revenue: $858,000
Shares: 5,629,370
Revenue: $858,000
Shares: 5,629,370
EV/Sales (Total value vs revenue — works when P/E can't)
API-0.34
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
89.3%
Gross Profit: $766,000
Revenue: $858,000
Revenue: $858,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-3,270.9%
Operating Income: -$28.06M
Revenue: $858,000
Revenue: $858,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,046.4%
Net Income: -$8.98M
Revenue: $858,000
Revenue: $858,000
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-15.5%
Net Income: -$8.98M
Total Equity: $57.96M
Total Equity: $57.96M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-105.6%
Operating Income: -$28.06M
Tax Rate: 0.0%
Equity: $57.96M
Total Debt: $0.00
Cash: $31.37M
Tax Rate: 0.0%
Equity: $57.96M
Total Debt: $0.00
Cash: $31.37M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
14.50
Current Assets: $61.25M
Current Liabilities: $4.22M
Current Liabilities: $4.22M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $57.96M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $57.96M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.15
Revenue: $858,000
Shares: 5,629,370
Shares: 5,629,370
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$10.30
Total Equity: $57.96M
Shares: 5,629,370
Shares: 5,629,370
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-5.30
Operating CF: -$29.81M
CapEx: $0.00
Shares: 5,629,370
CapEx: $0.00
Shares: 5,629,370
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $16.00
Stock Price: $16.00
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$8.98M
Net Income: -$8.98M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares RLYB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 5:29pm (16h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $636,000 | $858,000 |
| Cost of Revenue | $109,000 | $167,000 | $150,000 | $131,000 | $92,000 |
| Gross Profit | $-109,000 | $-167,000 | $-150,000 | $636,000 | $766,000 |
| Operating Expenses | $45.6M | $67.9M | $78.9M | $61.1M | $28.8M |
| Operating Income | -$45.6M | -$67.9M | -$78.9M | -$60.5M | -$28.1M |
| Net Income | -$47.0M | -$66.7M | -$74.6M | -$57.8M | -$9.0M |
| EBITDA | -$45.4M | -$67.7M | -$78.8M | -$60.4M | -$28.0M |
| EPS | $-11.68 | $-16.72 | $-14.72 | $-10.64 | $-1.59 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 5:29pm (16h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $175.3M | $57.0M | $24.5M | $13.9M | $31.4M |
| Total Current Assets | $180.9M | $179.5M | $114.8M | $67.8M | $61.3M |
| Total Assets | $182.2M | $180.4M | $115.6M | $68.1M | $62.3M |
| Current Liabilities | $6.6M | $10.7M | $9.3M | $6.2M | $4.2M |
| Long-Term Debt | $0 | $374,000 | $0 | $0 | $0 |
| Total Liabilities | $6.6M | $11.1M | $9.4M | $6.5M | $4.3M |
| Total Equity | $175.6M | $169.3M | $106.2M | $61.7M | $58.0M |
| Retained Earnings | -$94.0M | -$160.7M | -$235.2M | -$293.0M | -$302.0M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 5:29pm (16h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$45.5M | -$57.3M | -$60.3M | -$49.3M | -$29.8M |
| Capital Expenditure | $-333,000 | $-54,000 | $-12,000 | $0 | $0 |
| Free Cash Flow | -$45.9M | -$57.3M | -$60.3M | -$49.3M | -$29.8M |
| Acquisitions (net) | -$2.0M | $-300,000 | -$2.3M | -$2.0M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $35.1M | -$118.4M | -$32.5M | -$10.6M | $17.5M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 5:29pm (16h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$80,000 $80,000 – $80,000
|
$87.9M $87.9M – $87.9M
|
$87.5M $87.5M – $87.5M
|
$89.0M $89.0M – $89.0M
|
| EBITDA |
$15,999 $15,999 – $15,999
|
$17.6M $17.6M – $17.6M
|
$17.5M $17.5M – $17.5M
|
$17.8M $17.8M – $17.8M
|
| Net Income |
-$31.1M -$31.1M – -$31.1M
|
-$64.9M -$64.9M – -$64.9M
|
-$17.6M -$17.6M – -$17.6M
|
$22.1M $22.1M – $22.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 5:29pm (16h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | +34.9% |
| Gross Profit Growth | -53.2% | +10.2% | +524.0% | +20.4% |
| Operating Income Growth | -48.7% | -16.3% | +23.4% | +53.6% |
| Net Income Growth | -41.8% | -11.9% | +22.5% | +84.5% |
| EBITDA Growth | -49.2% | -16.3% | +23.4% | +53.7% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for RLYB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for RLYB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30